STRATA Skin Sciences, Inc.(SSKN)Earnings, Financials & Key Ratios

SSKN•NASDAQ

$0.12

Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryAesthetics, dermatology, and wound care

AboutSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.Show more

Revenue$31M-8.5%
EBITDA-$1M+65.3%
Net Income-$6M+37.9%
EPS (Diluted)-1.35-419.2%
Gross Margin58.25%+2.5%
EBITDA Margin-4.46%+62.1%
Operating Margin-19.01%+31.1%
Net Margin-20.4%+32.1%
ROE-158.91%-39.1%

SSKN Price & Volume

STRATA Skin Sciences, Inc. (SSKN) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Masks Structural Liquidity Risks

Investment Thesis • Updated 2025Q4

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Liquidity and solvency constraints

Key Thesis Takeaways

STRATA Skin Sciences faces a challenging transition as it attempts to scale the TheraClear X platform amidst a shrinking asset base and persistent operational losses.
While the company maintains a 60.4% gross margin, the inability to achieve operating leverage, evidenced by SG&A costs consistently exceeding $5.5 million, suggests significant execution risk.
Investors should monitor the company's precarious liquidity position, as the current ratio of 0.58 and a debt-to-equity ratio of 5.59 indicate a high probability of future dilutive financing requirements.

Verdict Logic

the company's liquidity is severely constrained with a current ratio of 0.58 and a history of negative free cash flow, suggesting that the $7.9 million cash balance may be insufficient to support long-term operational scaling.

SSKN Growth Metrics

STRATA Skin Sciences, Inc. (SSKN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years5.2%

5 Years5.86%

3 Years-5.32%

TTM-8.54%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM35.7%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-271.59%

Return on Capital

10 Years-18.26%

5 Years-26.85%

3 Years-35.73%

Last Year-46.1%

Peers Comparison

Key metrics vs top competitors for STRATA Skin Sciences, Inc. (SSKN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
SSKNSTRATA Skin Sciences, Inc.Current	$0.12	$705.41K	-0.09	-8.54%	-20.4%	-158.91%	—
DERMJourney Medical Corporation	$6.75	$185.63M	-14.35	10.2%	-14.82%	-35.57%	—
SKINThe Beauty Health Company	$1.11	$143.86M	-6.94	-10.02%	-2.03%	-9.41%	—
LNTHLantheus Holdings, Inc.	$103.41	$6.73B	30.33	0.5%	18.05%	24.33%	—
INMDInMode Ltd.	$14.54	$921.24M	10.17	-6.16%	23.27%	13.28%	—
AEYEAudioEye, Inc.	$7.41	$92.58M	-29.64	14.52%	-9.05%	-70.95%	—